Out in open

The more, the merrier. Join and conjoin!

Thursday, July 05, 2007

The Future of Celebrex

The Future of Celebrex

            Most people who take Celebrex are probably unaware that COX-2 inhibitors lived a double life, as both painkillers and potential cancer therapies. After Vioxx was pulled from the market in September of 2004, the future of Celebrex (at least as a cancer prevention therapy), now appears to be in question. This was after Pfizer announced in 2005 that it was cancelling all cancer trials related to Celebrex. No one is for sure whether or not Celebrex will fade from the spotlight or continue t! o become successful, as a cancer-fighting drug.  That's because cancer prevention and treatment trials using Celebrex were underway or about to begin, at the time Pfizer issued its announcement. Nationwide, cancer researchers are now studying the results of the two colon cancer trials that were already underway, involving the use of Celebrex, at the time of Pfizer's announcement. At this time, researchers are waiting for additional analyses to take place, before they make any decisions about which COX-2 inhibitor cancer studies should continue.